Genmab A/S Files 6-K, Confirms 20-F Annual Reporting
Ticker: GNMSF · Form: 6-K · Filed: Feb 29, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Feb 29, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: compliance, regulatory-filing, form-6k
TL;DR
**Genmab A/S just filed a standard 6-K, confirming their Form 20-F annual reporting and S-8 registration statement references.**
AI Summary
Genmab A/S, a pharmaceutical preparations company, filed a Form 6-K with the SEC on February 29, 2024, for the month of February 2024. This filing indicates that Genmab A/S, with Commission File Number 001-38976, will file annual reports under Form 20-F. The report also states that it will be incorporated by reference into Genmab A/S's registration statements on Form S-8 (File Nos. 333-232693 and 333-262970).
Why It Matters
This routine filing confirms Genmab's ongoing compliance with SEC reporting requirements, providing transparency to investors regarding its financial and operational status.
Risk Assessment
Risk Level: low — This is a routine compliance filing with no new material information that would indicate a change in risk.
Key Numbers
- 001-38976 — Commission File Number (Genmab A/S's SEC identifier)
- 333-232693 — Form S-8 File Number (Genmab A/S's registration statement)
- 333-262970 — Form S-8 File Number (Genmab A/S's registration statement)
Key Players & Entities
- Genmab A/S (company) — Registrant
- SEC (company) — regulatory body
- February 2024 (date) — period of report
- February 29, 2024 (date) — filing date
- 001-38976 (dollar_amount) — Commission File Number
- 333-232693 (dollar_amount) — Form S-8 File Number
- 333-262970 (dollar_amount) — Form S-8 File Number
FAQ
What is the purpose of Genmab A/S's 6-K filing on February 29, 2024?
The 6-K filing by Genmab A/S on February 29, 2024, is a routine report of a foreign private issuer, confirming its intent to file annual reports under Form 20-F and noting that this report is incorporated by reference into its Form S-8 registration statements (File Nos. 333-232693 and 333-262970).
Under which form will Genmab A/S file its annual reports?
Genmab A/S will file its annual reports under Form 20-F, as indicated in the 6-K filing.
What is Genmab A/S's Commission File Number?
Genmab A/S's Commission File Number is 001-38976, as stated in the filing.
Into which other SEC filings is this 6-K report incorporated by reference?
This 6-K report is incorporated by reference into Genmab A/S's registration statements on Form S-8, specifically File Nos. 333-232693 and 333-262970.
What is the filing date of this 6-K report?
The filing date of this 6-K report is February 29, 2024.
Filing Stats: 232 words · 1 min read · ~1 pages · Grade level 15.4 · Accepted 2024-02-29 11:47:00
Filing Documents
- tmb-20240229x6k.htm (6-K) — 18KB
- tmb-20240229xex99d1.htm (EX-99.1) — 52KB
- tmb-20240229xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-002129.txt ( ) — 78KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF FEBRUARY 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-232693 and 333-262970 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: FEBRUARY 29, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated February 29, 2024: Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons